XENETIC BIOSCIENCES, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
XENETIC BIOSCIENCES, INC. (XBIO) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $429.58 thousand as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $429.58K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.98M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.24M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.17M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $429.58K 10-K · filed 2026-03-12 |
| 2024-12-31 | $1.98M 10-K · filed 2026-03-12 |
| 2023-12-31 | $2.24M 10-K · filed 2025-03-18 |
| 2022-12-31 | $2.17M 10-K · filed 2024-03-21 |
| 2021-12-31 | $2.05M 10-K · filed 2023-03-22 |
| 2020-12-31 | $1.96M 10-K · filed 2022-03-22 |
| 2019-12-31 | $2.07M 10-K · filed 2021-03-16 |
| 2018-12-31 | $1.86M 10-K · filed 2020-03-26 |
| 2017-12-31 | $1.53M 10-K · filed 2019-03-29 |
| 2016-12-31 | $1.53M 10-K · filed 2018-03-30 |
| 2015-12-31 | $1.31M 10-K · filed 2017-03-31 |
| 2014-12-31 | $52.32K 10-K · filed 2016-03-30 |
| 2013-12-31 | $409.39K 10-K · filed 2015-07-20 |
| 2012-12-31 | $462.98K 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |